Compass

HEALTH, MARGINALLY CHEAPER

02/10/19 -"The Health (ex Pharma) sector has lost ground over the last month but this reflects more a risk-on market context than a genuine sell-off in this expensive territory. Health stocks have been losing ..."

PDF page sample
Pages
48
Language
English
Published on
02/10/19
Download
You may also be interested by these reports :
19/06/26
We have reduced FY2025/26 and FY2026/27 adjusted EPS estimates by c.12%, primarily to reflect substantial increases in operating costs, particularly ...
22/05/26
Considering the operational challenges highlighted in the H1 26 trading update, we have incorporated assumptions of softer revenue growth and a ...
21/05/26
Elior’s H1 figures missed consensus and triggered a severe FY guidance downgrade, primarily reflecting lagging effects in converting recent contract ...
21/05/26
Mitchells & Butlers delivered a softer-than-expected H1 FY2025/26 performance, with slowing Q2 sales momentum and weaker drinks demand weighing on ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO